Takeda Development Center Americas, Inc. recalls Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 15 mg/1000 mg, Rx Only, 30 tablet bottle, D…
- Recall date
- September 10, 2018
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- D-0026-2019
- FDA classification
- Class II
- Brand / firm
- Takeda Development Center Americas, Inc.
- Sold / distributed
- AR, LA, MS, NC, NJ, OH, PA, SC and Puerto Rico
Why it was recalled
Defective Delivery System: tablets may be missing, in whole or in part, the laser drilled holes on the metformin core of the Actoplus met XR tablets.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 15 mg/1000 mg, Rx Only, 30 tablet bottle, Distributed by: Takeda Pharmaceuticals America, Inc, Deerfield, IL 60015. NDC: 64764-510-30
Get recall alerts
Free email alert whenever Takeda Development Center Americas, Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Takeda Development Center Americas, Inc.